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(IC95% [1.14–10.94]; P = 0.03) more chances to have Nd:Yag
laser than ReSTOR® eyes, after adjusting for age at surgery.
CONCLUSIONS:This analysis conducted at one year suggested
that following usual surgical practice in a private setting,
ReSTOR® eyes had signiﬁcantly less capsulotomy than those
implanted with Acrilisa®. Avoiding Nd:Yag laser and its potential
complications is important, especially in a young population.
Analyses at two and three years will be required to conﬁrm these
ﬁndings
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IMPACT OF COMPLIANCE ON INTRA-OCULAR PRESSURE
(IOP) CONTROL IN GLAUCOMA PATIENTS
Lafuma A1, Laurendeau C1, Jeanbat V1, Berdeaux G2
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OBJECTIVES: To identify and characterize glaucoma patient
compliance proﬁles and to evaluate the impact on treatment
efﬁcacy. METHODS: A computerized device (Travalert®) that
collects daily instillation time and number of drops was given to
a cohort of patients for three months. A patient was declared
compliant when at least 2 drops per day were instilled, one in
each eye. Two compliance rates were calculated per week: during
the weekend and the remaining ‘working’ days. Principal com-
ponent analysis (PCA) was performed followed by an ascendant
hierarchical classiﬁcation (AHC) to identify groups of compliant
patients. Their characteristics were compared using chi-square or
ANOVA. RESULTS: A total of 113 patients were included (mean
age 66.5, 51.8% male), and 86.7% had primary open angle
glaucoma. Mean IOP was 24.2 mmHg before using Travalert®.
57.5% were treated with DuoTrav® and 42.5% with Travatan®.
PCA identiﬁed two axes (compliance intensity and week effect),
explaining 63.0% of the variance. AHC identiﬁed 3 compliance
groups: good (56.6% of the patients, compliance around 80%),
mild (21.2% of the patients, compliance around 50%) and poor
(22.1% of the patients, compliance around 20%). No predictive
variables (demographic or medical) of poor compliance were
identiﬁed. At the last visit, IOP was 16.1 mmHg on average and
statistically signiﬁcantly higher in the poor compliance group
(17.7 mmHg; P = 0.02). CONCLUSIONS: Compliance, mea-
sured objectively with a medical device, remains a major issue in
glaucoma treatment since about half the patients had compliance
lower than 80%. This impacted IOP control, a surrogate end-
point of glaucoma progression. None of the medical and demo-
graphics variables were associated with poor compliance
suggesting that forthcoming compliance research should identify
new targets (e.g. behavior) to identify patients beneﬁting from a
compliance training program.
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EFFECTIVENESS OF MOXIFLOXACIN INTHETREATMENT OF
BACTERIAL CONJUNCTIVITIS IN ADULTS
Lafuma A1, Koshnood B1, Laurendeau C1, Berdeaux G2
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France
OBJECTIVES: To estimate the effectiveness of moxiﬂoxacin in
the treatment of bacterial conjunctivitis in adults using data
from the available randomized clinical trials METHODS: Four
randomized clinical trials were identiﬁed. Three compared
moxiﬂoxacin against placebo and one against oﬂoxacin. Effec-
tiveness parameters included early (day 3 to 5) and late (day 7
to 10) clinical efﬁcacy, late bacteriological efﬁcacy, and drop-out
due to lack of efﬁcacy. Fixed (Mantel-Haenzel) and random
(Der Simonian and Laird) effects models for risk ratios and risk
differences associated with treatment effects were estimated and
tests of homogeneity of effects across studies were done. All
analyses were conducted on the intention to treat population.
RESULTS: A total of 609 moxiﬂoxacin-treated patients and 606
placebo-treated patients were included in the meta-analysis.
Drop-out rates due to lack of efﬁcacy were consistently higher
for patients receiving placebo. However, there was signiﬁcant
heterogeneity in the estimates of drop-out rates for moxiﬂoxa-
cin and placebo groups across studies (p = 0.04). The probabil-
ity of both an early and a late clinical remission was higher with
moxiﬂoxacin (RR, 1.17, P = 0.001; RR, 1.13; P = 0.05, respec-
tively). The late bacteriological remission rate was about 25%
higher (RR, 1.26, P = 0.001) for patients treated with moxi-
ﬂoxacin. Eleven patients had to be treated with moxiﬂoxacin to
gain one additionanl clinical remission and 6 to gain one more
bacteriological remission. In comparison to oﬂoxacin, the prob-
ability of drop-out due to lack of efﬁcacy for the bacteriologi-
cally documented population was 2.63-fold lower (P = 0.03)
with moxiﬂoxacin; one extra failure could be avoided for every
19 patients treated. CONCLUSIONS: This meta-analysis sug-
gests higher clinical and bacteriological efﬁcacy of Moxiﬂoxacin
compared with placebo. The estimates reported here should be
interpreted with caution, given the small number of clinical
trials with published results. The lower proportion of drop-outs
for patients treated with moxiﬂoxacin compared with oﬂoxacin
suggests a lower use of rescue treatments for patients receiving
moxiﬂoxacin.
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OBJECTIVES: To compare the efﬁcacy of topical ocular
hypotensives for the treatment of intraocular hypertension and
glaucoma. Adverse events that may affect patients’ willingness to
comply with treatment were also assessed. METHODS: A sys-
tematic review was conducted to identify randomized controlled
trials in patients with glaucoma or ocular hypertension with a
prostaglandin analogue treatment arm. A total of 181 eligible
articles were identiﬁed with 73 suitable for meta-analysis. A
mixed treatment comparison (MTC) was performed to estimate
the relative efﬁcacy of the treatments. Studies connected to
latanoprost and reporting the mean and standard deviation in
absolute intraocular pressure (IOP) at three months were used in
the MTC since this maximised the analysis dataset. Baseline IOP
was included as a covariate in the MTC. Random effects models
were used, as study variance indicated some degree of heteroge-
neity. A second MTC was conducted to estimate the rate of
hyperaemia-type adverse events. RESULTS: The mean IOP at
three months for latanoprost is 17.42 mmHg from a baseline of
23.5 mmHg. Latanoprost is statistically signiﬁcantly better at
lowering IOP versus timolol, and latanoprost and timolol is
statistically signiﬁcantly more efﬁcacious versus latanoprost
alone. There were no further statistically signiﬁcant differences in
mean IOP for latanoprost versus any other treatments. The
hyperaemia event rate for latanoprost is 25.18%. Using the odds
ratio results compared to latanoprost, timolol has a statistically
signiﬁcantly lower event rate. Travoprost, bimatoprost, tra-
voprost and timolol, bimatoprost and timolol, latanoprost and
brimonidine, latanoprost and dorzolamide have statistically sig-
niﬁcantly higher event rates. CONCLUSIONS: The results indi-
cate that there is no clinically relevant difference in IOP lowering
between treatments except for timolol. However there are
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signiﬁcant differences in adverse events. In actual practice such
events affect a patients’ willingness to comply with treatment and
therefore the effectiveness of treatment.
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ATOPIC DERMATITIS IN CHILDHOOD:WHAT
“DERMATOLOGICAL FUTURE” FORTHESE CHILDREN?
Misery L1, Boussetta S2,Taieb C2
1Hopital Morvan, Brest, France, 2Pierre Fabre, Boulogne, France
OBJECTIVES: To understand the « dermatological future » of
subjects having suffered from atopic dermatitis as a child.
METHODS: In each of the 8 following European countries
(France, Italy, Spain, Portugal, Germany, Switzerland, Belgium
and Greece) a sample of the population, representative of the
population over the age of 15, was established by CSA Santé.
Hence, 4506 individuals were interviewed by phone and selected
according to the quotas method. RESULTS: A total of 12.5% of
our sample (54% of women) declared having suffered from
atopic dermatitis ; this ﬁgure is relatively stable in each country
with two extremes: the lowest rate was found in Portugal (6.5%)
and the highest rate was seen in Belgium and France with 14.8
and 14.4% respectively. A total of 17.8% said they had never
consulted a dermatologist whereas they are 31% in the general
population. A total of 51% declared having today dry skin (vs
38%) and 57% said they had sensitive or very sensitive skin (vs
31.8%). A total of 10.3% of subjects with a history of atopic
said they were currently suffering from atopic dermatitis (2.3%)
or contact eczema (8%) hence 3 times more than in the global
population. Similarly, 27% declared a coexisting pathology
during the interview, they are only 12.3% in the general popu-
lation (acne: 5%, psoriasis: 3.3%, seborrheic dermatitis: 1.35%).
These results are twice those observed in the general population.
CONCLUSIONS: Recent studies have indicated atopic dermati-
tis in 10 to 25% of children whereas studies performed in the 60s
gave prevalence rates of the order of 5%. Our results (at 12%)
therefore conﬁrm these ﬁgures. Furthermore, according to our
results, it appears that subjects with a history of atopic dermatitis
are more exposed than the general population to dermatoses
which is why preventive patient management and adapted edu-
cation measures are of particular interest.
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SENSITIVE SCALP:AN EPIDEMIOLOGICAL APPROACH
Misery L1, Boussetta S2,Taieb C2
1Hopital Morvan, Brest, France, 2Pierre Fabre, Boulogne, France
OBJECTIVES: Using an epidemiological approach, evaluate and
analyse subjects who consider their scalp to be sensitive.
METHODS: A representative sample of the population aged 15
years old and over was taken by CSA Santé. A total of 1011
individuals were questioned by telephone and selected as per the
quotas method. RESULTS: Statistically more women than men
considered themselves to be “someone who has a very or rather
sensitive scalp” (47.4% vs 40.8%, p = 0.036). While 5.7% of the
total population declared that they suffered from a scalp disorder,
11.5% of these were in the sensitive population vs 1.1% in the
non-sensitive population (p < 0.001). 24% of responders com-
plained of dry scalp, 58% had a normal scalp, 16% an oily scalp
and 1% a mixed scalp. A total of 60.3% of responders with a dry
scalp also considered that they had a very or rather sensitive
scalp, while this percentage dropped to 58.4% in responders
with oily scalps and ﬁnally to 32.9% in those with a normal scalp
(p < 0.001). Subjects with a sensitive skin experienced statisti-
cally more frequent stinging, itching and burning than those with
non-sensitive scalps. The primary trigger factors were pollution
for 54%, heat for 42%, emotion for 47% and shampoo for 47%.
An emotional trigger was signiﬁcantly more frequent in patients
with a sensitive scalp than in the others (53.0% vs 41.4%.). A
total of 65.8% of subjects reported sensitive skin declared they
had a sensitive scalp vs 49.5% in the other responders
(p < 0.001). CONCLUSIONS: Numerous factors can trigger sen-
sitive scalp but not in a systematic fashion. This study made it
possible to establish a link between the concepts of sensitive skin
and sensitive scalp. Sensitive skin appears to be more frequently
observed in patients with a sensitive scalp. Finally, the symptoms
that characterise sensitive skin are not systematically the same as
those that deﬁne a sensitive scalp.
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SENSITIVE SKIN IN EUROPE:AN EPIDEMIOLOGICAL
APPROACH
Misery L1, Boussetta S2,Taieb C2
1Hopital Morvan, Brest, France, 2Pierre Fabre, Boulogne, France
OBJECTIVES: To establish a comparative description on the
perception of skin sensitivity in 8 European countries represent-
ing a total of 285 million inhabitants. METHODS: In each of the
8 following European countries (France, Italy, Spain, Portugal,
Germany, Switzerland, Belgium and Greece) a sample of the
population, representative of the population over the age of 15,
was established. Hence, 4506 individuals were interviewed by
phone and selected according to the quotas method. RESULTS:
When asked “Do you have sensitive skin?”, 37.6% of our sample
replied ‘sensitive’ or ‘very sensitive’. The non-reply rate was
below 1.5%. More women said they had sensitive skin than men,
49.4% versus 37% (p < 0.05). According to interviewed indi-
viduals, a dermatological disease was sometimes concomitant
with their skin sensitivity: 31.2% of subjects with very sensitive
skin declared suffering from a dermatological pathology, 17.6%
with sensitive skin, 8.7% with minor skin sensitivity and 3.7%
with no skin sensitivity. A history of atopic dermatitis or eczema
during childhood was more frequently observed in subjects with
sensitive or very sensitive skins (18.5% versus 8.6%). Inter-
viewed individuals who declared having dry or oily skin had
signiﬁcantly and more frequently sensitive or very sensitive skin
compared to those with normal skin. Fifty-two percent of indi-
viduals with dry skin; 38.4% with oily skin and only 25% with
normal skin. CONCLUSIONS: This study is the ﬁrst study on
sensitive skin carried among the European population. In
the eight concerned countries, 100,000,000 of subjects declared
having ’sensitive’ or ’very sensitive’ skin and probably not all
have spontaneously consulted their dermatologist for this type of
complaint. Dermatologists should therefore systematically ask
the question to their patient. The non-reply rate was very low,
which implies that the term ‘sensitive skin’ makes sense for the
great majority of individuals.
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SENSITIVE SKINS IN FRANCE:AN EPIDEMIOLOGICAL
APPROACH
Boussetta S,Taieb C
Pierre Fabre, Boulogne, France
OBJECTIVES: To evaluate the perception of skin sensitivity in
France. METHODS: A representative nationwide sample of the
French population aged 15 and over was taken. The individuals
were questioned by telephone and selected as per the quotas
method. RESULTS: To the question “Do you have sensitive
skin”, 44.1% of men and 59.4% of women answered “sensitive”
or “very sensitive”. Women had signiﬁcantly more sensitive skin
than men (p < 0.001). The no response rate was less than 1.0%.
A total of 27.7% of the population with very sensitive skin,
14.3% with sensitive skin, 7.0% with slightly sensitive skin and
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